Aubade for Aubagio: FDA approves teriflunomide in RRMS


The U.S. Food and Drug Administration has approved the use of oral teriflunomide (Aubagio) 7 or 14 mg/day for the treatment of relapsing forms of MS. The drug was submitted for FDA review in October 2011. The drug has not yet been approved by Health Canada.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page